NASDAQ:COAG Hemab Therapeutics (COAG) Stock Price, News & Analysis $47.55 +0.08 (+0.17%) As of 07/31/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Hemab Therapeutics Stock (NASDAQ:COAG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hemab Therapeutics alerts:Sign Up Key Stats Today's Range$45.44▼$48.6250-Day Range$24.98▼$50.3952-Week Range$23.00▼$52.15Volume447,286 shsAverage Volume315,500 shsMarket Capitalization$2.22 billionP/E RatioN/ADividend YieldN/APrice Target$48.00Consensus RatingModerate Buy Company Overview Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options. Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders. The company’s work combines biology and translational research to advance potential therapies from discovery through clinical development. Based on publicly available information, Hemab Therapeutics is headquartered in the United States and operates as part of the broader global biopharmaceutical industry. The company’s leadership includes a management team with experience in drug development and hematology-focused research.AI Generated. May Contain Errors. Read More Hemab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreCOAG MarketRank™: Hemab Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 745th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingHemab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Hemab Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageHemab Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Hemab Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hemab Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hemab Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.55% of the float of Hemab Therapeutics has been sold short.Short Interest Ratio / Days to CoverHemab Therapeutics has a short interest ratio ("days to cover") of 5.33.Change versus previous monthShort interest in Hemab Therapeutics has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHemab Therapeutics does not currently pay a dividend.Dividend GrowthHemab Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News SentimentHemab Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Hemab Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for COAG on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows1 people have added Hemab Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $55,459,603.00 in company stock, which represents 2.4973% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Hemab Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,459,603.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsHemab Therapeutics has minimal institutional ownership at this time.Read more about Hemab Therapeutics' insider trading history. Receive COAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COAG Stock News HeadlinesHemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives $48.00 Average PT from BrokeragesJuly 23, 2026 | americanbankingnews.comHemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical CatalystsJuly 15, 2026 | seekingalpha.com7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in secret, used fake names, and told absolutely no one where they were going. On November 22nd, 1910, seven of America's most powerful bankers gathered on Jekyll Island to design the Federal Reserve. Their goal? To create a system where they control the money supply and you foot the bill. That system has created $38 trillion in debt, destroyed 98% of the dollar's purchasing power, and now they're preparing the final move: Central bank digital currencies (CBDCs). But if you have at least $100,000 saved and you're concerned about what's coming, you need to hear this.August 2 at 1:00 AM | Decentralized Masters (Ad)Hemab Therapeutics Presents Sustained Sutacimig Bleed Reduction Data and Preclinical Factor VII Deficiency Results at ISTH 2026July 14, 2026 | quiverquant.comQHemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 CongressJuly 14, 2026 | globenewswire.comHemab Advances Bleeding Disorder PipelineJuly 13, 2026 | benzinga.comHemab Therapeutics Reports Positive HMB-002 Clinical Data in Von Willebrand Disease and Announces HMB-003 ProgramJuly 12, 2026 | quiverquant.comQHemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 CongressJuly 12, 2026 | globenewswire.comSee More Headlines COAG Stock Analysis - Frequently Asked Questions How have COAG shares performed this year? Hemab Therapeutics' stock was trading at $34.00 on April 30, 2026. Since then, COAG stock has increased by 39.9% and is now trading at $47.55. How were Hemab Therapeutics' earnings last quarter? Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) issued its earnings results on Thursday, May, 21st. The company reported ($23.98) earnings per share for the quarter. When did Hemab Therapeutics IPO? Hemab Therapeutics (COAG) raised $285 million in an initial public offering on Friday, May 1st 2026. The company issued 16,750,000 shares at a price of $16.00-$18.00 per share. When does Hemab Therapeutics' lock-up period expire? Hemab Therapeutics's lock-up period expires on Wednesday, October 28th. Hemab Therapeutics had issued 16,750,000 shares in its public offering on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. After the end of Hemab Therapeutics' lock-up period, company insiders and major shareholders will be able to sell their shares of the company. How do I buy shares of Hemab Therapeutics? Shares of COAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/21/2026Today8/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:COAG CIK2114044 WebN/A Phone(452) 138-7627FaxN/AEmployees72Year Founded2019Price Target and Rating Average Price Target for Hemab Therapeutics$48.00 High Price Target$55.00 Low Price Target$36.00 Potential Upside/Downside+0.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares46,705,000Free FloatN/AMarket Cap$2.22 billion OptionableN/A BetaN/A Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:COAG) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored7 Bankers Met in Secret (Now We Pay for It)A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredOne signature away. Expected within months.On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...Behind the Markets | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA New Gold Era Is Coming - Here's How to Help Protect Your Retirement NowWashington insiders are quietly talking about a coordinated move to revalue gold—and with the national debt ap...Preserve Gold | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemab Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemab Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COAG Stock Alerts